Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-dose and extension study of human protein C (TAK-662) in congenital protein C deficiency
jRCT2031210209Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of Protein C concentrate in congenital protein C deficiency, purpura fulminans (PF), Cutaneous necrosis and 2 more (2 arms), sponsored by Takeda. Primary endpoints: Protein C activity level of TAK-662, Terminal phase elimination half-life (t1/2) of TAK-662 and 6 more. Started Sep 2021; status: completed.
02
Drugs
Protein C concentrate
03
Conditions
congenital protein C deficiencypurpura fulminans (PF)Cutaneous necrosiswarfarin-induced skin necrosis (WISN)thromboembolism
Beyond the preview
Go deeper on jRCT2031210209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210209.